BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15613114)

  • 1. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
    Tsironi M; Deftereos S; Andriopoulos P; Farmakis D; Meletis J; Aessopos A
    Eur J Haematol; 2005 Jan; 74(1):84-5. PubMed ID: 15613114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L; Masera N; Russo P; Cirò A; Vincenzi A; Vimercati C; Masera G
    Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
    Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
    Tsiapras D; Fragatou S; Farmaki K; Kyrzopoulos S; Paraskevaidis I; Voudris V; Kremastinos D
    Hemoglobin; 2010 Jun; 34(3):210-20. PubMed ID: 20524811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
    Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S; Jabbari A; Cohan N; Haghpanah S
    Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
    Huang YC; Chang JS; Wu KH; Peng CT
    Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.